CA2784033A1 - A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection - Google Patents

A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection Download PDF

Info

Publication number
CA2784033A1
CA2784033A1 CA2784033A CA2784033A CA2784033A1 CA 2784033 A1 CA2784033 A1 CA 2784033A1 CA 2784033 A CA2784033 A CA 2784033A CA 2784033 A CA2784033 A CA 2784033A CA 2784033 A1 CA2784033 A1 CA 2784033A1
Authority
CA
Canada
Prior art keywords
antibody
patient
region
pcrv
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2784033A
Other languages
English (en)
French (fr)
Inventor
Geoffrey T. Yarranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanigen Inc
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of CA2784033A1 publication Critical patent/CA2784033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2784033A 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection Abandoned CA2784033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28897709P 2009-12-22 2009-12-22
US61/288,977 2009-12-22
PCT/US2010/061636 WO2011087799A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Publications (1)

Publication Number Publication Date
CA2784033A1 true CA2784033A1 (en) 2011-07-21

Family

ID=44224810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784033A Abandoned CA2784033A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Country Status (5)

Country Link
US (1) US8642039B2 (enExample)
EP (1) EP2515935A4 (enExample)
JP (1) JP2013515079A (enExample)
CA (1) CA2784033A1 (enExample)
WO (1) WO2011087799A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
CN107922482A (zh) * 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
US12264194B2 (en) 2019-03-13 2025-04-01 Medimmune, Llc Decreasing Staphylococcus aureus infections in colonized patients
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318536C (en) * 1998-11-25 2009-11-17 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen
BRPI0509026A (pt) * 2004-05-17 2007-09-18 Corus Pharma Inc formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
EP2203155A1 (en) * 2007-09-25 2010-07-07 Novartis Ag Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2010091189A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Also Published As

Publication number Publication date
WO2011087799A1 (en) 2011-07-21
US8642039B2 (en) 2014-02-04
JP2013515079A (ja) 2013-05-02
US20110165172A1 (en) 2011-07-07
EP2515935A4 (en) 2013-08-28
EP2515935A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
US8642039B2 (en) Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
AU2008333985B2 (en) Antibodies to the PcrV antigen of pseudomonas aeruginosa
TWI719938B (zh) 多重細菌感染之治療
JP2011505381A5 (enExample)
EP4032904A1 (en) Anti-alpha-hemolysin antibody and use thereof
JP2022163050A (ja) 院内肺炎を予防または治療する方法
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2024020236A2 (en) Monoclonal antibodies that interfere with iron uptake
US20240254219A1 (en) Novel wnt agonist antibodies and therapeutic uses thereof
CA3207447A1 (en) Antibodies that bind glucosaminidase and uses thereof
EA043404B1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161221